knowledge -WSS

knowledge

author：hotspot 2025-10-01 00:14:21 - browse：54595

empty test tubes in the hand. -- first opinion coverage from STAT — Adobe

The Food and Drug Administration on Friday announced its intention to start regulating tests developed in laboratories — closing the “Theranos loophole” that has allowed inaccurate tests to slip through the cracks.

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision. FDA Commissioner Robert Califf said at the time that if the bill failed, the agency would take matters into its own hands.

The proposed rule fulfills that promise, adding lab diagnostics to the list of devices that fall under FDA enforcement — a move that patient groups and non-lab test makers support, and that laboratories are likely to dispute. When the FDA started regulating medical devices in 1976, lab-developed tests were simple and offered mostly to local patient populations. The agency generally allowed labs to use these tests without submitting proof of their efficacy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： What to watch for from Zogenix and Amicus clinical trials

explore

WSS

An inside look at PIPEs, biotech's buzzy new financing tool

An inside look at PIPEs, biotech's buzzy new financing tool

How to address the problem of discarded donor organs

Truvian presents data for its desktop blood

FDA does about

Pfizer highlights cancer drugs it thinks could reignite investor interest

leisure time

knowledge

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

RSV vaccines may be linked to small increased risk of developing GBS

Alkermes shareholders re

Medical device lobby: We're tired of waiting on Medicare coverage

Apple is now the first public company to be valued at $3 trillion

Kenai launches with $82 million for Parkinson’s stem cell therapy

DIEP, the 'gold standard' of breast reconstruction, is under threat

How doctors’ personal politics affect patients

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

RSV vaccines may be linked to small increased risk of developing GBS

hotspot

The battle over 'scope creep' and who gets to be called 'doctor'

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Kenai launches with $82 million for Parkinson’s stem cell therapy

Biogen says it will cut costs by $700 million, slash 1,000 jobs

What causes rare myocarditis in young men after Covid vaccines?

New lawsuit accuses health insurer Cigna of denying claims in bulk

leisure time

Wikipedia

explore

explore